Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | PNP | P00491 | 1/20 | 0.30 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
| ▸ | KDM4B | O94953 | 1/20 | 0.30 |
| ▸ | KDM5C | P41229 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27324270 | 0.84 | HRH4 (0.33) | HRH4DPP4 | |
| SCHEMBL17364326 | 0.82 | AURKA (0.33) | ADORA2AADORA1PARP1KDM4AKDM4B | |
| SCHEMBL17364302 | 0.80 | CA12 (0.39) | ADORA2AADORA1PARP1CA12CA1 | |
| SCHEMBL3773140 | 0.78 | HRH4 (0.33) | HRH4DPP4 | |
| SCHEMBL17364332 | 0.77 | DPP4 (0.51) | ADORA2AADORA1CA12CA1CA2 | |
| SCHEMBL3780109 | 0.77 | ADORA2A (0.40) | ADORA2AADORA1HRH4 | |
| SCHEMBL8826198 | 0.71 | HRH4 (0.50) | HRH4 | |
| SCHEMBL8830247 | 0.71 | CHUK (0.48) | HRH4 | |
| SCHEMBL8830437 | 0.70 | CHUK (0.50) | HRH4 | |
| SCHEMBL8826309 | 0.70 | CHUK (0.50) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376219-A1 | Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods | ZHONG MINGHONG (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376219-A1 | Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods | ZHONG MINGHONG (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376219-A1 | Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods | ZHONG MINGHONG (US) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376219-A1 | Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods | PNP, ATIC, NT5C3B | ADORA2A 36/4885ADORA1 174/4885PARP1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.